Sign In
Buy KURA
$8.66
-0.315 (-3.51%)
At Close: Jun 03, 2026
Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin
04:02pm, Monday, 03'rd Nov 2025
– Milestone triggered by dosing of first patient in the second of two frontline AML Phase 3 clinical trials – – Milestone triggered by dosing of first patient in the second of two frontline AML
– Data to be featured in two oral presentations on December 8, 2025 – – Broad development program assesses ziftomenib across diverse AML segments and treatment paradigms to inform appropriate us
Kura Oncology's Ziftomenib Poised For Differentiation
09:00am, Sunday, 02'nd Nov 2025
Kura Oncology is reiterated as a strong buy, due to Ziftomenib's potential best-in-class safety profile in NPM1-mutated AML. Recent FDA approval of Syndax's Revuforj included a boxed warning for cardi
Kura Oncology to Report Third Quarter 2025 Financial Results
04:01pm, Tuesday, 28'th Oct 2025
SAN DIEGO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment
Kura Oncology, Inc. (NASDAQ:KURA) Receives Consensus Rating of “Moderate Buy” from Analysts
01:53am, Sunday, 26'th Oct 2025
Shares of Kura Oncology, Inc. (NASDAQ: KURA - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the fifteen research firms that are covering the company, MarketBeat.com
Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin
07:02am, Friday, 24'th Oct 2025
- Milestone triggered by dosing of first patient in frontline AML Phase 3 clinical program- SAN DIEGO, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharm
KLP Kapitalforvaltning AS Raises Stock Position in Kura Oncology, Inc. $KURA
03:02am, Wednesday, 22'nd Oct 2025
KLP Kapitalforvaltning AS increased its holdings in shares of Kura Oncology, Inc. (NASDAQ: KURA) by 179.4% in the undefined quarter, according to the company in its most recent Form 13F filing with th
Kura Oncology, Inc. (NASDAQ:KURA ) Discusses Clinical Updates on Farnesyl Transferase Inhibitor Programs and Combination Therapies in Oncology October 18, 2025 1:30 PM EDT Company Participants Troy Wi
FTI mechanism addresses innate and adaptive resistance pathways common to targeted oncology therapies Early clinical and preclinical data support darlifarnib's potential to enhance clinical benefit of
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:30am, Friday, 03'rd Oct 2025
SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicine
Kura Oncology, Inc. (KURA) Presents at UBS Virtual Oncology Day Transcript
05:02pm, Wednesday, 01'st Oct 2025
Kura Oncology, Inc. (NASDAQ:KURA ) UBS Virtual Oncology Day October 1, 2025 2:30 PM EDT Company Participants Troy Wilson - Chairman, CEO & President Conference Call Participants Xiaochuan Dai - UBS In
– Expanding clinical experience and safety profile of ziftomenib support its evaluation in combination with approved FLT3 inhibitors in frontline AML –
– KOMET-017-IC trial of intensive chemotherapy combination will assess MRD negative CR and EFS as dual-primary endpoints to support potential U.S. accelerated and full approval –
– KOMET-001 in R/R NPM1-m AML met its primary endpoint with ziftomenib monotherapy demonstrating significant clinical benefit and deep responses –
Kura Oncology to Participate in Upcoming Investor Conference
07:30am, Wednesday, 24'th Sep 2025
SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment
